Organization: Merck KGAA

Biomira inks major collaborative deal with Merck

Edmonton-based Biomira Inc has entered into a collaborative agreement with pharmaceutical giant Merck KGAA worth US$150 million in license, milestone payments and equity investments. The agreement is focused on Biomira’s two most advanced cancer drug candidates — Theratope and BLP25 — and involves further development and promotion. Biomira retains marketing rights in Canada and will…